Introduction {#S0001}
============

The human immunodeficiency virus (HIV) epidemic continues to be a major challenge to global health. In 2011, an estimated 34 million people were living with human immunodeficiency virus /acquired immunodeficiency syndrome (HIV/AIDS) worldwide; of them 22.9 million were living in Sub-Saharan Africa \[[@CIT0001]\]. According to 2011 Ethiopia Demographic Health survey (EDHS) and 2012 country report the estimated adult prevalence of HIV is 1.5% \[[@CIT0002]--[@CIT0004]\]. In Ethiopia considering the magnitude of the problem use of Highly Active Antiretroviral therapy (HAART) started in 2003 as a fee based treatment and then launched free ART in 2005 and by the end of January 2009 an estimated 180,447 clients had been enrolled in ART \[[@CIT0005]\]. According to HEALTH SECTOR DEVELOPMENT PROGRAMME (HSDP) national report the total number of HIV positive people was estimated at 1,216,908 and out of them, 397,818 were eligible for ART, 333,434 ever started and 247,805 currently on ART \[[@CIT0006]\]. According to 2010 Ethiopian national report only 865 adults and 13pediatric patients are on second line regimen which accounts only 0.6%. Immunological failure is defined as: fall of CD4 count to pre-therapy base line, 50% fall from the on treatment peak value, or persistent CD4 levels below 100cells/mm3 \[[@CIT0004]\]. Knowing factors that can help to predict treatment failure will help to identify clients that are at higher risk of treatment failure so as to change regimen for those who already have failed regimen and delay though maximizing follow in those have potential failure. Routine patient follow-up need to be done as part of the routine clinical follow up and need to have a high index of suspension. Studies shows that only a few patients among those who actually had treatment failure were detected at the ART centers. The mean duration of treatment failure on first line ART and the mean duration from detection of treatment failure to switch to second line ART were longer \[[@CIT0003]\]. Different studies from South Africa, Malawi, Ethiopia and Haiti revealed that the prevalence of treatment failure range from 9.8% -15% \[[@CIT0006], [@CIT0003]\]. There are various risk factors described in different studies and world health Organization (WHO) guidelines \[[@CIT0007]\]. Yet published data on determining of magnitude and associated factors of Immunological failure are limited. Risk factors for Immunological failure have not been studied in this area. So the aim of this study was to assess the magnitude and associated factors of Immunological failure among adult and adolescent HIV infected Patients (with age ≥15yrs) on HAART and to provide information to optimize assessing of Immunological failure among HIV patients on HAART.

Methods {#S0002}
=======

Study area and period {#S20003}
---------------------

The study was conducted in St. Luke and Tulubolo Hospitals, south west Shoa zone, Oromia region St. Luke hospital is located in Woliso town and at distance of 125 Km and Tulubolo hospital is located in Tulubolo town which is 95 km away from Addis Ababa, the capital city of Ethiopia. St. Luke Hospital ever enrolled HIV positive clients/patients to chronic HIV care starting from April 2006-July 2013 who\'s age ≥15 years is 3478 (F=2134, M=1344) and patients ever started on Highly Active Antiretroviral Therapy (HAART) for the same age and period is 2126 (F=1225, M=901). For Tulubolo Hospital number of patients ever enrolled in HIV chronic care starting from May 2010-July 2013 (the Hospital has started ART service in May 2010) who\'s age ≥15 years is 218 (F=142, M=76) and patients put on Highly Active Antiretroviral Therapy (HAART) for the same age is 130 (F=82, M=48) and the study period was from April 2006 up to July 2013.

Study design {#S20004}
------------

Institutional based retrospective follow up study was carried out among HIV-positive patients on HAART for ≥12 months. Hence the chart of HIV positive patients on HAART for ≥12 months between April 2006 and July 2013 were reviewed retrospectively.

Source population {#S20005}
-----------------

Source population was all human immune Deficiency Virus (HIV) infected patients with age ≥15yrs who were on first line Antiretroviral Therapy (ART) regimen in St. Luke and Tulu Bolo Hospitals.

Study population {#S20006}
----------------

The study population was all HIV infected patients with age ≥15yrs who started first line ART in St. Luke and Tulu Bolo Hospitals since April 2006-July 2013.

**Sample size determination** Double proportional formula

nj=Zα/2√(1+1/r)P(1-P)+Zβ√P1(1-P1)+P2(1-P2)/r (P1-P2)2

was used to determine the sample size of the study; EPI-info version 3.5.3 window is used with type 1 error 5%, power of 80% and ratio of exposed to unexposed 1:1, and the sample size has been calculated for exposure status in different variables using the following formula. Proportion of exposure status in these variables is taken from previous studies \[[@CIT0008], [@CIT0009]\]. And the final sample size for the study was 828.

### Sampling procedure

Two hospitals which are found in south west shoa zone were used. From both hospitals HIV patients on HAART for ≥12 months has been were selected. The calculated final sample size was 828 with zero none response rate. Systematic random sampling is employed after proportional allocation of the sample for both Hospitals.

Study variables {#S20007}
---------------

The dependent variable of the study was immunologic failure. The independent variables include Socio demographic characteristics, Behavioral status and Base line clinical and Laboratory information.

Data collection methods and instrument used {#S20008}
-------------------------------------------

To ensure consistency of the data electronic data base, registrations and patient charts was used to extract the data. The data were collected by preparing chart abstraction form.

Data quality control {#S20009}
--------------------

Before data collection the data collectors and supervisors were get a one day orientation by principal investigator. The data collectors were Hospitals data clerks and the supervisors were Hospitals ART providers. There was a regular supervision to data collectors by the principal investigator and supervisors to maintain the data quality.

Data analysis {#S20010}
-------------

The data was entered to Epi-data 3.1 version and analyzed using SPSS version 20. Descriptive analysis using frequency and summary statistics was conducted to describe the study subject. Immunologic failure distribution within groups in respect to time after initiation of therapy is estimated using Kaplan Meier method and log rank tests. Bivariate Cox regression analysis has been used to determine the association between independent variables and covariates with significant association (p value

Ethical consideration {#S20011}
---------------------

The study was approved by an ethical committee in Addis Continental Institute of Public Health. A support letter to the two Hospitals was obtained from the institute before conducting the data collection. The information that was collected by the study were stored in a file and kept confidential.

Results {#S0012}
=======

**Base line socio demographic and socio clinical character:** from a total of 828 patients data reviewed retrospectively 57.6% (477) of them were female. 61.1% (506) were married and followed by 14.7% (122) widower, 10.4% (86) never married. The median age of the participant at enrollment was 32.00 year (IQR, 27-39yrs) and 45.7% (378) go through primary education ([Table 1](#T0001){ref-type="table"}).

###### 

Baseline socio demographic characteristics of HIV patients on HAART in St.Luke and Tulubolo Hospitals, April 2006-July 2013.(n=828),Ethiopia

  -----------------------------------------------------------------
  Variable                                    Frequency   Percent
  ------------------------------------------- ----------- ---------
  **Age**                                                 

   15-24                                      81          9.8

   25-34                                      377         45.5

   35-44                                      253         30.6

    \>=45                                     117         14.1

  **Sex**                                                 

   Male                                       351         42.4

   Female                                     477         57.6

  **Marital status**                                      

   Never Married                              86          10.4

   Married                                    506         61.1

   Divorced                                   44          5.3

   Separated                                  70          8.5

   Widowed                                    122         14.7

  **Educational status**                                  

   No Education                               198         23.9

   Primary                                    378         45.7

   Secondary                                  214         25.8

   Tertiary                                   38          4.6

  **Patient referral**                                    

   From within the facility or hospital       688         83.1

   From outside the facility                  140         16.9

  **Employment status**                                   

   Employed                                   279         33.7

   Unemployed                                 549         66.3

  **Religion**                                            

   Orthodox                                   530         64.0

   Muslim                                     105         12.7

   Protestant                                 175         21.1

   Catholic                                   12          1.4

   [\^](#TF0001){ref-type="table-fn"}Others   6           0.7

  **Condition of spouse**                                 

   Healthy                                    175         21.1

   Chronically ill\                           221\        26.7\
   Dead                                       102         12.3

   Unknown                                    255         30.8
  -----------------------------------------------------------------

Patients other than mentioned religions

**Base line clinical and laboratory information:** about 82.5% of patients were working in their functional status at a time of enrollment. The commonest documented OI at time of enrollment were herpes Zoster, followed by oral thrush and TB which accounts 22.3%, 15.8% and 13.7% respectively. At base line the median CD4 count was 148cells/mm3 (IQR, 100-200) and the mean Hemoglobin was 12.08g/dl (SD, 1.934). 99.5%(824) were given cotrimoxzole at the time of ART initiation. At base line 33.5%(278) of the participants were on WHO staging 3 and 4. Thirty nine point two percent (325) of participants know their spouse HIV status ([Table 2](#T0002){ref-type="table"}).

###### 

Base line clinical and laboratory information of HIV patients on HAART in St.Luke and Tulu Bolo Hospitals, Ethiopia, April 2006-July 2013 (N=828)

  Variable                frequency   Percent
  ----------------------- ----------- ---------
  **Weight**                          
    \< 50                 461         55.7
    ≥ 50                  367         44.3
  **Functional status**               
   Working                670         80.9
   Ambulatory             133         16.1
   Bedridden              25          3.0
  **WHO stage**                       
   Stage 1                281         33.9
   Stage 2                316         38.2
   Stage 3                183         22.1
   Stage 4                48          5.8
  **Base line CD4**                   
    ≤ 200cell/mm3         619         74.8
    \> 200cell/mm3        201         24.3
  **Base line CPT**                   
   Yes                    824         99.5
   No                     4           0.5
  **Base line TB**                    
   Yes                    109         13.2
   No                     719         86.8
  **Base line Hgb**                   
   \< 9 g/dl              53          6.4
   9-11 g/dl              207         25
   \> 11 g/dl             568         68.6

**Magnitude of Immunological failure:** a total of 828 patients were followed retrospectively for a median time of 44 months (IQR 32-56) with a minimum of 18 and maximum 97 months follow up from April 2006-July 2013. Out of 828 patients 6.8% (56) developed immunological failure. The incidence of immunological failure was 1.8 cases per 100 person years of follow-up.

**Time of Immunological failure:** the median time of failure for those qualified immunological failure was 48 months (IQR 35-65 months). Life table showed treatment failure started by 24 month follow-up with 16% and similarly 13%, 6%, 26%, 14%, 12% for the month of 30, 36, 42, 48, and 54 respectively. A sharp drop is seen at 84th month. Life table distribution and the survival function curve is shown in [Table 3](#T0003){ref-type="table"} and [Figure 1](#F0001){ref-type="fig"}. The findings of survival functions between groups were compared using Kaplan-Meier method. To see the significant differences between the groups the Log rank test was used and the result is shown in [Table 4](#T0004){ref-type="table"}, [Table 5](#T0005){ref-type="table"}.

![Cumulative probability of not developing immunological failure for patients after initiation of HAART, St.Luke and Tulu Bolo Hospital, April 2006-July 2013](PAMJ-21-291-g001){#F0001}

###### 

Life table distribution of probability of immunological failure of patients on HAART St.Luke and Tulu Bolo Hospital, Ethiopia, April 2006-July 2013

  \*Interval Start Time   Number Entering Interval   Number Withdrawing during Interval   Number Exposed to Risk   Number of Terminal Events   Proportion Terminating   Proportion Surviving   Cumulative Proportion Surviving at End of Interval
  ----------------------- -------------------------- ------------------------------------ ------------------------ --------------------------- ------------------------ ---------------------- ----------------------------------------------------
  0                       65                         0                                    65.000                   0                           0.00                     1.00                   1.00
  6                       65                         0                                    65.000                   0                           0.00                     1.00                   1.00
  12                      65                         0                                    65.000                   0                           0.00                     1.00                   1.00
  18                      65                         0                                    65.000                   0                           0.00                     1.00                   1.00
  24                      65                         1                                    64.500                   10                          0.16                     0.84                   0.84
  30                      54                         0                                    54.000                   7                           0.13                     0.87                   0.74
  36                      47                         1                                    46.500                   3                           0.06                     0.94                   0.69
  42                      43                         2                                    42.000                   11                          0.26                     0.74                   0.51
  48                      30                         1                                    29.500                   4                           0.14                     0.86                   0.44
  54                      25                         0                                    25.000                   3                           0.12                     0.88                   0.39
  60                      22                         1                                    21.500                   8                           0.37                     0.63                   0.24
  66                      13                         2                                    12.000                   1                           0.08                     0.92                   0.22
  72                      10                         0                                    10.000                   5                           0.50                     0.50                   0.11
  78                      5                          0                                    5.000                    3                           0.60                     0.40                   0.04
  84                      2                          1                                    1.500                    1                           0.67                     0.33                   0.01

Six month interval was taken from the WHO and National guide line which is recommended for immunological follow-up

###### 

Kaplan-Meier and log rank analysis for comparison of survival time for patients on HAART according to base line information, April, 2006-July, 2013. (N=828)

  Variable                                Mean survival   95% Confidence Interval          
  --------------------------------------- --------------- ------------------------- ------ -------
  **Sex**                                                                                  0.083
   Male                                   54.8            48.1                      61.6   
   Female                                 47.6            41.3                      53.9   
  **Age**                                                                                  0.56
   15-24                                  44.4            33.9                      54.8   
   25-34                                  52.9            44.6                      61.2   
   35-44                                  51.8            44.3                      59.3   
    \>=45                                 51.7            40.5                      62.9   
  **Education**                                                                            0.056
   NoEducation                            47.5            37.8                      57.1   
   Primary                                48.0            41.4                      54.7   
   Secondary                              56.8            47.9                      65.6   
   Teritiary                              77.6            67.5                      87.8   
  **Marital status**                                                                       0.67
   Never Married                          47.3            34.1                      60.5   
   Married                                52.4            46.3                      58.4   
   Divorced                               61.5            59.4                      63.5   
   Separated                              51.0            44.4                      57.5   
   Widowed                                47.3            32.2                      62.3   
  **Patient referral**                                                                     0.48
   From within the facility or hospital   50.6            45.5                      55.7   
   From outside the facility              63.0            53.1                      72.8   

###### 

Kaplan-Meier and Log rank analysis for comparison of survival time for patients on HAART according to base line information, April, 2006-July, 2013. (N=828)

  Variable                 Mean survival   95% Confidence Interval   Log rank test   
  ------------------------ --------------- ------------------------- --------------- -----------------------------------------
  Disclosure status                                                                  0.016[\#](#TF0002){ref-type="table-fn"}
   Yes                     54.4            48.3                      60.5            
   No                      45.3            39.5                      51.1            
  Weight at baseline                                                                 0.23
    \< 50                  53.3            46.9                      59.6            
    \>=50                  49.0            42.1                      55.9            
  WHO stage at base line                                                             0.3
   Stage1                  45.4            36.0                      54.9            
   Stage2                  54.2            48.1                      60.4            
   Stage3                  52.9            40.0                      65.7            
   Stage4                  64.5            54.7                      74.2            
  OI at base line                                                                    0.17
   Yes                     53.9            48.8                      59.0            
   No                      45.6            34.6                      56.7            
  Base line CD4                                                                      0.013[\#](#TF0002){ref-type="table-fn"}
    \<=200                 54.9            48.9                      60.9            
    \> 200                 43.5            37.0                      50.0            
  Functional status                                                                  0.2
   Working                 49.3            44.2                      54.3            
   Ambulatory              61.7            50.9                      72.4            
   Bedridden               50.5            8.3                       92.6            
  Past TB treatment                                                                  0.15
   Yes                     63.375          50.7                      76.0            
   No                      49.964          45.0                      54.8            

p-value \<0.05

**Predictors of Immunological failure:** in bivariate Cox regression CD4 count and disclosure of HIV status were statistically significant. Significance difference was seen for two variables. When survival time for disclosure status was compared, those patients who didn\'t disclose their HIV status to family member had significantly lower mean survival time, 45.3 with P value=0.016. Significant difference was seen between CD4 count below or equal to 200cell/mm3 and greater than 200cell/mm^3^, time to failure in the latter group was shorter (P value=0.013). No significant association was observed between age, sex, educational status, employment status, marital status, and base line weight of the patient, presence of OI, baseline WHO stage, baseline functional status, presence of past TB and time to Immunological failure. The variable that were found to be significantly associated with immunological failure in bivariate and those with P-value ≤0.2 in Bivariate Cox regression were entered in to multivariate Cox-model. Age and sex was also entered in to the model irrespective of their association to immunological failure as they are the commonest confounders. The multivariate model analysis made evident that disclosure status was significantly associated with immunological failure at P-value less than 0.05 and from the Bivariate Cox regression, functional status was found to be significantly associated with immunological failure. Patients who didn\'t disclose their HIV status to any one had high risk of developing immunological failure compared with patients those who had disclose their HIV status (AHR, 0.429; 95% CI 0.206 - 0.893; P-value=0.024). Patients with base line functional status ambulatory had risk of developing immunological failure than patients with working and bedridden functional status (HR, 0.337; 95% CI 0.137-0.828; P-value=0.018) ([Table 6](#T0006){ref-type="table"}, [Table 7](#T0007){ref-type="table"}).

###### 

Cox proportional hazard analysis with bivariate and multivariate model for socio demographic, clinical and laboratory, HIV patients on HAART in St.Luke and Tulu Bolo Hospital, Ethiopia, from April 2006-July 2013. (n=828)

  Variable                     Immunological failure (%)   Immunological success (%)   Crude HR (95% CI)       Adjusted HR[\#](#TF0003){ref-type="table-fn"}(95% CI)
  ---------------------------- --------------------------- --------------------------- ----------------------- -------------------------------------------------------
  **Sex**                                                                                                      0.737(0.323-1.683)
   Male                        30(8.5)                     321(91.5)                   1                       
   Female                      26(5.5)                     451(94.5)                   0\. 627 (0.365-1.075    
  **Age**                                                                                                      
   15-24                       5(6.2)                      76(93.8)                    1                       
   25-34                       23(6.1)                     354(93.9)                   1.847 (0.610-5.591)     
   35-44                       19(7.5)                     234(92.5)                   0.913 (0.6416-2.00)     
    \>=45                      9(7.7)                      108(92.3)                   0.978 (0.440-2.172)     
  **Education**                                                                                                
   No Education                12(6.1)                     186(93.9)                   1                       
   Primary                     30(7.9)                     348(92.1)                   1.023 (0.543-2.040)     
   Secondary                   13(6.1)                     201(93.9)                   0.635 (0.284-1.418)     
   Teritiary                   1(2.6)                      37(97.4)                    0.125 (0.016-0.967)     
  **Patient referral**                                                                                         
   From within the hospital    50(7.3)                     638(92.7)                   1                       
   From outside the facility   6(4.3)                      134(95.7)                   1.352 (0. 574 -3.180)   

HR- Hazard Ratio, @ Statistically significant

###### 

Cox proportional hazard analysis with bivariate and multivariate model for socio demographic, clinical and laboratory, HIV patients on HAART in St.Luke and Tulu Bolo Hospital, Ethiopia from April 2006-July 2013. (n=828)

  Variable                          Immunological failure (%)   Immunological success (%)   Crude HR (95% CI)       Adjusted HR[\#](#TF0004){ref-type="table-fn"} (95% CI)
  --------------------------------- --------------------------- --------------------------- ----------------------- --------------------------------------------------------
  **Disclosure status**                                                                                             
   Yes                              38(6.8)                     517(93.2)                   2.056(1.120-3.774)      0.429(0.206-0.893)[@](#TF0005){ref-type="table-fn"}
   No                               18(6.6)                     255(93.4)                   1                       1
  **WHO stage**                                                                                                     
   Stage 1                          17(6.1)                     264(93.9)                   1                       
   Stage 2                          25(7.9)                     291(92.1)                   1.916 (0.637-5.761)     
   Stage3                           10(5.5)                     173(94.5)                   1.182(0.408-3.426)      
   Stage4                           4(8.3)                      44(91.7)                    1.124 (0. 342-3.688)    
  **Base line CD4 count (N=820)**                                                                                   0.517(0.253-1.057)
    \<=200                          38(6.1)                     581(93.9)                   0.469 (0.252-0.872)     
    \> 200                          16(8)                       185(92)                     1                       
  **Functional status**                                                                                             
   Working                          43(6.4)                     627(93.6)                   1                       1
   Ambulatory                       11(8.3)                     102(91.7)                   0\. 557 (0.274-1.130)   0.337(0.137-0.828)[@](#TF0005){ref-type="table-fn"}
   Bedridden                        2(8)                        23(92)                      1.044 (0 .250-4.354)    0.599(0.111-3.216)
  **Weight**                                                                                                        
   \<50                             34(7.4)                     427(92.6)                   0.718 (0.412-1.253)     
   \>=50                            22(6)                       345(94)                     1                       

HR- Hazard Ratio

Statistically significant

Discussion {#S0013}
==========

In this retrospective follow-up study Patients on follow-up contributed a total of 3116 person years and incidence of immunological failure was 1.8 per 100 person years of follow-up (PYFUS). From the study found that the independent significant predictors of Immunological failure in patients living with HIV/AIDS after initiation of ART were not disclosing of HIV status to any one of family member and being ambulatory in baseline functional status. As per the WHO and/national ART guide line definition 6.8% of patients had developed immunological failure. The finding is consistent with the finding from India where the prevalence of Immunological failure is 7.3% in participants who had been on HAART for a median of 17 months (IQR:6-30 months) and study conducted in Kenya which shows immunological failure 5.7% \[[@CIT0010]--[@CIT0013]\]. The median pre HAART CD4 count observed in this study is 148cell/ mm^3^ which is also comparable with studies conducted in Djibuti with median CD4 count 144cell/mm^3^ and study conducted in Tanzania with median CD4 count 159 cells/mm^3^ (IQR; 65-234) \[[@CIT0008], [@CIT0011], [@CIT0014]\]. In bivariate cox regression base line CD4 count ≥ 200/mm^3^ was statistical association in Immunological failure, In contrast studies conducted in India and other sites showed that low Cd4 count (13,8\].

Limitation of the study {#S20014}
-----------------------

This study was conducted retrospectively on Patients chart review. So that most reviewed charts have got missed laboratory tests like platelet counts and pre HAART viral load determination was not included in the study due to absence of Viral load laboratory test in the hospitals.

Conclusion {#S0015}
==========

According to this study the majority of patients with immunological failure were not diagnosed timely and not switched to second line regimen. So knowing the predictor factors and timing of failure are important parts for care and treatment. Having ambulatory functional status at base line and disclosing of HIV status to family members has identified the independent significant predictors of immunological failure in patients living with HIV/AIDS after initiation of HAART by this study. Based on the finding, the following recommendations were forwarded. Baseline CD4 counts \>200cell/mm^3^ should needs further study, sensitization of health care providers to focus on immunological failure and health care providers should be guided to focus on predictors of immunological failure.
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